Atopic dermatitis: the new frontier

Harris, Victoria R; Cooper, Alan J

doi:10.5694/mja17.00463

ARTICLE
AUTHORS
REFERENCES

Topics

Immune system diseases

Pharmaceutical preparations

Skin and connective tissue diseases

Summary

Atopic dermatitis (AD) is the most common inflammatory skin condition in adults and children.
AD is a chronic disease that has a considerable negative impact on the quality of life of patients and their families.
Most cases of AD may be effectively treated with topical therapies that are directed at decreasing cutaneous inflammation and alleviating pruritus. These therapies include emollients, antihistamines, topical corticosteroids, topical calcineurin inhibitors and antimicrobial and antiseptic measures; more refractory cases may require additional oral immunosuppression (eg, cyclosporine, azathioprine, methotrexate and mycophenolate).
Improved understanding of the immune pathogenesis of AD, including the role of T helper cells and the inflammatory pathways involved, has led to breakthrough translational clinical research and treatment.
New targeted immunotherapies, such as inhibitors of interleukin (IL)-4, IL-13, IL-31, Janus associated kinase and phosphodiesterase, have had promising results from phase 2 and 3 trials for patients with moderate to severe AD.

Royal North Shore Hospital, Sydney, NSW

Correspondence: Victoria.harris@health.nsw.gov.au

Competing interests:

No relevant disclosures.

1. Hanifin JM, Reed ML. A population-based survey of eczema prevalence in the United States. Dermatitis 2007; 18: 82-91.
2. Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy 2007; 37: 526-535.
3. Simpson E, Thomas B, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016; 74: 491-498.
4. Wollenberg A, Orange A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30: 729-747.
5. Gittler JK, Shemer A, Suarez-Farinnas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterises acute and chronic dermatitis. J Allergy Clin Immunol 2012; 130: 1344-1354.
6. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387: 1109-1122.
7. Palmer C, Irvine AD, Terron-Kwiatkowski A. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-446.
8. Rupnik H, Rijavec M, Korosec P. Filaggrin loss-of-function mutations are not associated with atopic dermatitis that develops in late childhood or adulthood. Br J Dermatol 2015; 172: 455-462.
9. Narkajima S, Kitoh A, Egawa G, et al. IL17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Invest Dermatol 2014; 134: 122-130.
10. Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2015; 73: 311-318.
11. Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy 2015; 7: 1043-1058.
12. Lias P, Wakefield J. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clin Rev Allergy Immunol 2011; 41: 282-295.
13. Biedermann T. Dissecting the role of infections in atopic dermatitis. Acta Derm Venereol 2006; 86: 99-109.
14. Niebuhr M, et al. Staphylococcal exotoxins are strong inducers of IL22: a potential role in atopic dermatitis. J Allergy Clin Immunol 2010; 126: 1176-1183 e4
15. Deckers IA, McLean S, Linssen S, et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLoS One 2012; 7: e39803.
16. Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol 2017; 13: 15-26.
17. Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387: 40-52.
18. Simpson E, Chalmers J, Hanifin J. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014; 134: 818-823.
19. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-1160.
20. Francis N, Ridd M, Thomas-Jones E, et al. Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care. Ann Fam Med 2017; 15: 124-130.
21. Huang J, Abrams M, Tlougan B, et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Paediatrics 2009; 123: e808-e814.
22. Eichenfield LF, Wynnis TL, Berger TG. Guidelines for the care and management of atopic dermatitis. J Am Acad Dermatol 2014; 71: 116-132.
23. Schmitt J, von Koletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164: 415-428.
24. Smith SD, Stephens AM, Werren JC, Fischer GO. Treatment failure in atopic dermatitis as a result of parental health belief. Med J Aust 2013; 199: 467-469. <MJA full text>
25. Hong E, Smith SD, Fischer G. Evaluation of the atrophogenic potential of topical corticosteroids in paediatric dermatology patients. Pediatr Dermatol 2011; 28: 393-396.
26. Mooney E, Rademaker M, Dailey R, et al. Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement. Australas J Dermatol 2015; 56: 241-251.
27. Smith SD, Farrugia LL, Harris V, et al. Evaluation of the influence of family and friends, and the Internet on patient perceptions of long-term topical corticosteroid use. J Dermatolog Treat 2017; doi: 10.1080/09546634.2017.1306017 [Epub ahead of print].
28. Smith S, Hong E, Fearns S, et al. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas J Dermatol 2010: 51: 168-174.
29. Smith S, Harris V, Lee A, et al. General practitioners’ knowledge about use of topical corticosteroids in paediatric atopic dermatitis in Australia. Aust Fam Physician 2017; 46: 335-340.
30. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
31. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005; 6: 65-77.
32. Hanifin JM. Phosphodiesterase and immune dysfunction in atopic dermatitis. J Dermatol Sci 1990; 1: 1-6.
33. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-56.
34. Paller A, Tom W, Lebwohl M, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75: 494-503.
35. Bissonnette R, Papp KA, Poulin Y. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016; 175: 902-911.
36. Rubel D. Biologics beyond psoriasis [unpublished presentation]. 50th Annual Scientific Meeting of the Australasian College of Dermatologist; Sydney (Australia), 6-9 May 2017.
37. Silva SH, Guedes ACM, Gontijo B, et al. Influence of narrow-band UVB phototherapy on cutaneous microbiota of children with atopic dermatitis. J Eur Acad Dermatol Venereol 2006; 20: 1114-1120.
38. Meagher LJ, Wines N, Cooper A. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002; 43: 247-254.
39. Salek MS, Finlay AY, Luscombe DK. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993; 129: 422-430.
40. Granlund H, Erkko P, Remitz A, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol 2001; 81: 22-27.
41. Goujon C, Bérard F, Dahel K. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006; 16: 155-158.
42. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol 2001; 26: 369-375.
43. Yee J, Orchard D. Monitoring requirements for oral azathioprine, methotrexate and cyclosporine in a paediatric dermatology clinic and literature review. Australas J Dermatol 2016; doi: 10.1111/ajd.12526 [Epub ahead of print].
44. Kim DH, Park KY, Kim BY, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013; 38: 496-500.
45. Noda S, Krueger J, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 2015; 135: 324-336.
46. Ezzat MHM, Hasan ZE, Shaheen KYA. Serum measurement of inteleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 2011; 25: 334-339.
47. Levy L, Urban J, King B, et al. Treatment of recalcitrant atopic dermatitis with the oral Janus Kinase Inhibitor tofacinib citrate. J Am Acad Dermatol 2015; 73: 395-399.
48. Beck L, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate to severe atopic dermatitis. N Engl J Med 2014; 371: 130-139.
49. Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006; 118: 930-937.
50. Thaci D, Simpson E, Bieber T, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387: 40-52.
51. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
52. Lebwohl M, Strober B, Menter A. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373: 1318-1328.
53. Weiss D, Schaschinger M, Ristl R, et al. Ustekinumab treatment in severe atopic dermatitis: down-regulation of T-helper 2/22 expression. J Am Acad Dermatol 2017; 76: 91-97e3.
54. Samorano LP, Hanfin JM, Simpson El, et al. Inadequate response to ustekinumab in atopic dermatitis – a report of two patients. J Eur Acad Dermatol Venereol 2016; 30: 522-523.
55. Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 2017; 376: 826-835.
56. Fleischmann R, Kremer J, Cush J. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507.
57. Volf E, Au S, Dumont N, et al. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol 2012; 11: 341.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Atopic dermatitis: the new frontier

Topics

Summary

Author

Comment

Do you have any competing interests to declare? *